EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A landscape analysis of clinical trials in cancer pain management: current trends and emerging therapeutic targets

Jiaqi Cao, Xiaoyi Yu, Wei Lu

Frontiers in Oncology · 19.05.2026 · 16

DOI: 10.3389/fonc.2026.1795684 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 19.05.2026. Verfasst von Jiaqi Cao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Anesthesiology, Guizhou Medical University, Guiyang, Guizhou, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite a growing volume of clinical research, cancer pain management remains dependent on opioid-centric paradigms with few therapeutic breakthroughs. To identify innovation gaps and guide future research, a systematic evaluation of the global clinical trial landscape is imperative.

Methods

We conducted a comprehensive landscape analysis of 632 interventional cancer pain trials(1994-2025) from the Trialtrove database. Key characteristics including temporal trends, trial phases, therapeutic targets, and primary endpoints were extracted and analyzed.

Results

Our analysis revealed a significant “innovation paradox.” Although trial initiations have increased 3.2-fold since 2000, research remains focused on established mechanisms. Late-stage (Phase III, 38%) investigations predominated over scarce early-phase (Phase I, 13%) studies. Over half (52%) of all trials targeted opioid receptors, while emerging targets like NaV1.7 (18%)—a peripheral sodium channel implicated in inherited pain syndromes—and cannabinoid receptors (5%) were underrepresented. All percentages reflect proportions of the total 632 trials and categories may overlap. Furthermore, primary endpoints overwhelmingly favored unidimensional pain intensity scales (35.8%) over functional or quality-of-life (QoL) metrics. The most advanced innovations are currently limited to dual-mechanism agents (e.g., tapentadol combining MOR agonism and norepinephrine reuptake inhibition) and novel delivery systems (e.g., iontophoretic transdermal patches or intrathecal pumps).

Conclusion

The cancer pain research ecosystem exhibits substantial volume growth unmatched by mechanistic innovation. To surmount this therapeutic stagnation, future priorities must include expanding early-phase trials on novel pathways (e.g., tumor-microenvironment interactions), adopting composite endpoints integrating pain with function and QoL, and leveraging real-world evidence and AI-driven phenotyping to advance precision analgesia. This paradigm shift is critical to addressing the multidimensional burden of cancer pain.

Schlagwörter

Stichwörter der Autor:innen

cancer painclinical trialsopioidsprecision medicinetrial landscape

Autor:innen und Institutionen

  • Anesthesiology, Guizhou Medical University, Guiyang, Guizhou, China.
  • Pain Management Department, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.

Zitieren

APA

Cao, J., Yu, X., & Lu, W. (2026). A landscape analysis of clinical trials in cancer pain management: current trends and emerging therapeutic targets. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1795684

Vancouver

Cao J, Yu X, Lu W. A landscape analysis of clinical trials in cancer pain management: current trends and emerging therapeutic targets. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1795684

BibTeX
@article{Cao2026,
  author = {Cao, Jiaqi and Yu, Xiaoyi and Lu, Wei},
  title = {A landscape analysis of clinical trials in cancer pain management: current trends and emerging therapeutic targets},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1795684}
}
Kostenlos starten →